Adavosertib not checked

AstraZeneca · MK-1775 · AZD 1775

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
2 active
16 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.”In the company’s words, NCT03330847 on ClinicalTrials.gov
Tested for
Metastatic Triple Negative Breast Cancer, Muscle Invasive Bladder Cancer
Main trialPhase 2
“This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (Ceralasertib \[AZD6738\]) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple-negative breast cancer (TNBC) prospectively stratified by presence/absence of qualifying tumour mutation in genes involved in the homologous recombination repair (HRR) pathway. Treatment arms are olaparib…”In the company’s words, NCT03330847 on ClinicalTrials.gov
Other names
MK-1775 · AZD 1775

Other drugs for Metastatic Triple Negative Breast Cancer

All 151 drugs for Metastatic Triple Negative Breast Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials16

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 13 Nov 2020 To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Phase 1Active, not recruiting 18 Mar 2020 Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
Phase 2Completed 8 Aug 2016 A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
Phase 2Completed 13 Dec 2018 Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2Completed 22 Jun 2020 A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Phase 2Completed 23 May 2022 A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
Phase 1/2Terminated 13 Jun 2011 A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)
Phase 1Terminated 15 Jun 2011 A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Phase 1Completed 6 Jan 2014 A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
Phase 1Completed 25 Jan 2018 Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
Phase 1Completed 26 Apr 2018 Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
Phase 1Completed 22 Apr 2019 Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
Phase 1Completed 22 Sep 2021 Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
Phase 1Terminated 16 Nov 2021 Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib
Phase 1Terminated 21 Apr 2022 A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
Phase 1Terminated 1 Jun 2022 A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Adavosertib

Following is part of Solo: you see every change to Adavosertib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in